Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Net Margin (2022 - 2025)

Stoke Therapeutics has reported Net Margin over the past 4 years, most recently at 4124.39% for Q4 2025.

  • For Q4 2025, Net Margin fell 407715.0% year-over-year to 4124.39%; the TTM value through Dec 2025 reached 3.67%, up 24029.0%, while the annual FY2025 figure was 3.71%, 23904.0% up from the prior year.
  • Net Margin for Q4 2025 was 4124.39% at Stoke Therapeutics, down from 360.68% in the prior quarter.
  • Over five years, Net Margin peaked at 71.19% in Q1 2025 and troughed at 4124.39% in Q4 2025.
  • A 4-year average of 811.55% and a median of 684.35% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: surged 91632bps in 2024 and later crashed -407715bps in 2025.
  • Year by year, Net Margin stood at 786.32% in 2022, then fell by -23bps to 963.56% in 2023, then skyrocketed by 95bps to 47.24% in 2024, then tumbled by -8631bps to 4124.39% in 2025.
  • Business Quant data shows Net Margin for STOK at 4124.39% in Q4 2025, 360.68% in Q3 2025, and 169.96% in Q2 2025.